A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This is a study to compare the antitumor activity of ramucirumab (IMC-1121B) and eribulin
together versus eribulin alone, in participants with locally recurrent or metastatic breast
cancer.